ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

Core Viewpoint - Atara Biotherapeutics, Inc. is facing a securities class action lawsuit due to allegations of misleading statements regarding the regulatory prospects of its product tabelecleucel, which may impact the company's financial condition and business operations [2]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from May 20, 2024, to January 9, 2026 [2]. - Allegations include that Atara failed to disclose manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of tabelecleucel unlikely [2]. - The lawsuit claims that these undisclosed issues heightened regulatory scrutiny risks and jeopardized ongoing clinical trials, likely leading to significant negative impacts on Atara's business and financial condition [2]. Group 2: Shareholder Actions - Shareholders who purchased ATRA shares during the class period are encouraged to register for the class action, with a lead plaintiff appointment deadline set for May 22, 2026 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [4].